The occurrence of cerebral vasospasm after aneurysmal subarachnoid hemorrhage (SAH) is a signifi cant event resulting in decreased cerebral blood fl ow and oxygen delivery. Prevention and treatment of cerebral vasospasm is vital to avert neurological damage and reduced functional outcomes. A variety of pharmacotherapy interventions for the prevention and treatment of cerebral vasospasm have been evaluated. Unfortunately, very few large randomized trials exist to date, making it diffi cult to make clear recommendations regarding the effi cacy and safety of most pharmacologic interventions. Considerable debate exists regarding the effi cacy and safety of hypervolemia, hemodilution, and hypertension (triple-H therapy), and the implementation of each component varies substantially amongst institutions. There is a new focus on euvolemic-induced hypertension as a potentially preferred mechanism of hemodynamic augmentation. Nimodipine is the one pharmacologic intervention that has demonstrated favorable effects on patient outcomes and should be routinely administered unless contraindications are present. Intravenous nicardipine may offer an alternative to oral nimodipine. The addition of high-dose magnesium or statin therapy has shown promise, but results of ongoing large prospective studies are needed before they can be routinely recommended. Tirilazad and clazosentan offer new pharmacologic mechanisms, but clinical outcome results from prospective randomized studies have largely been unfavorable. Locally administered pharmacotherapy provides a targeted approach to the treatment of cerebral vasospasm. However, the paucity of data makes it challenging to determine the most appropriate therapy and implementation strategy. Further studies are needed for most pharmacologic therapies to determine whether meaningful effi cacy exists.
INTRODUCTION
Aneurysmal subarachnoid hemorrhage (SAH) is a devastating neurologic condition that accounts for up to 5% of all cerebrovascular accidents and affects approximately 30,000 people each year in the United States. [1] [2] [3] Patients who survive the initial cerebrovascular event are at high risk of further complications including rebleeding, cerebral vasospasm, and delayed cerebral ischemia. Rebleeding after SAH occurs in 5% to 10% of patients and is most likely Volume 49, November 2014 to occur in the fi rst 72 hours after the initial hemorrhage. 4 Early intervention utilizing coil embolization or microsurgical clip ligation reduces rebleeding risk. 5 Cerebral vasospasm typically occurs between 3 and 14 days after SAH, with a peak incidence approximately 1 week after the original event. Vasospasm is described as intracranial artery narrowing caused by arterial vasoconstriction, vascular endothelium enlargement, or subendothelial fi brosis. 6 A variety of mechanisms including infl ammatory, immunologic, free radical production, and alterations in ion channels have been proposed to cause these deregulations in vessel constriction and relaxation. Release of vasoconstrictors, including serotonin and certain prostaglandins, from the platelets has been identifi ed as a potential cause of early vasospasm. 7 However, oxyhemoglobin release during erythrocyte lysis may be the primary culprit catalyzing these pro-vasospasm mechanisms. 7, 8 This pathophysiologic mechanism is supported by the observation that patients with thick blood in the ventricles or basal cistern (Fisher grading scale of 4) appear to be at the highest risk for cerebral vasospasm. 9 The diagnosis of vasospasm is preferably determined by direct visualization on radiographic images, but it may also be assumed when alterations in cerebral blood fl ow velocities are observed via sonography. 10 The occurrence of cerebral vasospasm is an important event, because it results in decreased cerebral blood fl ow and oxygen delivery that ultimately result in delayed cerebral ischemia or infarction. If the vasospasm persists and cannot be controlled, further neurological damage and reduced functional outcomes are likely to be observed. [11] [12] [13] Applying appropriate monitoring strategies to identify, prevent, or manage cerebral vasospasm is a critical component of treating patients with SAH. Frequent neurological assessment and determination of any new neurological defi cits are the key methods for clinical identifi cation of potential vasospasm and delayed cerebral ischemia. These repeated physiological assessments can also be supplemented with transcranial Doppler (TCD) ultrasonography. Not all events can be found on clinical examination. Digital subtraction angiography, computed tomography with angiography or perfusion imaging, or magnetic resonance imaging increase specifi city. These radiological monitoring strategies should be used upon identification of any new alterations in consciousness, focal defi cits, or alterations in cerebral blow fl ow velocities identifi ed via TCD. The radiological monitoring is also particularly useful for asymptomatic patients or those who cannot participate in neurological assessments.
Radiological confi rmation of cerebral vasospasm and/ or delayed cerebral ischemia should trigger intervention. 14 The purpose of this review is to evaluate the pharmacotherapy interventions for the prevention and treatment of cerebral vasospasm in patients with SAH. a variety of mechanisms including diuresis, negative nitrogen balance, decreased erythropoiesis, and iatrogenic blood loss. 16 Hypovolemia appears to be a cumulative process, and decreased circulating blood volume is most prevalent in patients undergoing surgical intervention 6 to 72 hours post SAH. 17 It has been postulated that because hypovolemia and fl uid restriction are risk factors for cerebral vasospasm-induced delayed cerebral ischemia, prophylactic induction of hypervolemia should help alleviate this by increasing blood volume and cerebral blood fl ow. Hypervolemia created by volume expansion may prevent cerebral ischemia by increasing cardiac fi lling pressures and increasing cardiac output and blood pressure. Additionally, isotonic fl uid administration may lower blood viscosity and decrease cerebrovascular resistance, thereby improving blood rheology. 18 Hypervolemia versus normovolemia for prevention of cerebral vasospasm. Historically, hypervolemia was used frequently as both a preventative and a treatment method for cerebral vasospasm and delayed cerebral ischemia; however, data from the last decade have brought its prophylactic use into question. A prospective randomized study of 82 patients evaluated hypervolemia versus normovolemia fl uid management that began the day after aneurysm clipping. All patients received dextrose 5% water with 0.9% sodium chloride at 80 mL/h for 14 days. The hypervolemic group patients received albumin 5% every 2 hours to achieve a target pulmonary artery diastolic pressure (PADP) of ≥14 mm Hg or a central venous pressure (CVP) of ≥8 mm Hg thereafter. Normovolemic patients received albumin 5% 250 mL every 2 hours to achieve a PADP of ≥7 mm Hg or CVP of ≥5 mm Hg. The results of the study demonstrated that cerebral blood fl ow was not improved with hypervolemia compared to normovolemia. Additionally, there were no differences in patients experiencing symptomatic vasospasm (8 patients in each group), patients requiring hypertensive therapy (6 patients normovolemia vs 7 patients hypervolemia), or functional independence post discharge (66% in each group). The authors concluded that induction of hypervolemia did not confer additional benefi t over normovolemia in SAH patients. 19 Similarly, a study of 32 patients compared triple-H therapy to normovolemic fl uid therapy. In the normovolemic fl uid group, patients received baseline infusions of 1,000 mL dextrose 5% water and 1,000 mL 0.9% sodium chloride every day until day 12. Fluid management was targeted to maintain a neutral fl uid balance. In the triple-H fl uid management group, fl uid management was titrated to achieve a CVP of 8 to 12 mm Hg, a hematocrit of 30% to 35%, and a mean arterial pressure (MAP) of more than 20 mm Hg greater than the preoperative MAP value. Patients received 2,000 mL of dextrose 5% water and 2,000 mL of 0.9% sodium chloride daily. Additionally, patients received 1,000 to 1,500 mL of albumin 4% until day 12. Dopamine 5 to 15 mcg/kg/min was administered to achieve MAP goals. A nonsignifi cant decrease in clinical symptoms of vasospasm was demonstrated in the triple-H group (31.5% vs 25%), but there was no difference in TCD identifi ed vasospasm or functional outcomes between groups. Patients in the triple-H group had higher average daily costs and higher rates of congestive heart failure, which were attributed to the additional fl uid therapy. 20 Even though the premise of hypervolemia therapy and the early positive fi ndings within historical studies drove the routine utilization of this approach, the most recent data suggest that there is no benefi t on cerebral blood fl ow or patient outcomes. There may actually be increased risk to the patient including increased incidence of bleeding, congestive heart failure, pulmonary edema, cerebral edema, and infections. 21, 22 Therefore, hypervolemia cannot be recommended for prophylaxis of cerebral vasospasm. 23 Hypervolemia for treatment of cerebral vasospasm. Although the prophylactic use of hypervolemia is no longer recommended, it is still frequently utilized for the treatment of cerebral vasospasm. Even in this setting, the effi cacy and safety of hypervolemia as an individual component of triple-H therapy has to be reconsidered. Very few studies to date have evaluated the isolated effects of volume expansion on the reversal of vasospasm or its effects on intracranial pressure, cerebral blood fl ow, and brain tissue oxygenation. In a study of 6 euvolemic patients who developed clinical signs of vasospasm, administration of 0.9% sodium chloride 15 mL/kg over 1 hour was effective at improving cerebral blood fl ow and reducing cerebral ischemia. 24 This effect was demonstrated without any substantial effects on pulmonary artery occlusion pressure (PAOP), MAP, cardiac output, or CVP and was sustained for 2 to 3 hours. A study of 16 patients with severe vasospasm documented by angiography evaluated the effi cacy of hypervolemia (mean 1,000 mL/day colloid plus 3,740 mL/day Volume 49, November 2014 crystalloid; mean CVP increase from 5.4 to 7.3 cm H 2 O), phenylephrine-induced hyptertension (mean MAP increase from 102 mm Hg to 132 mm Hg), or dobutamine-enhanced cardiac output (mean cardiac index increased from 4.1 to 6 L/min/m 2 ) on cerebral blood fl ow. Contrary to the fi ndings in the previously mentioned study, improvements in cerebral blood fl ow were only found in patients receiving phenylephrine or dobutamine. 25 Similarly, an observational study of 45 patients demonstrated that moderate hypertension increased brain tissue oxygenation in 90% of cases with a complication rate of 8% compared to hypervolemia, which was only effective in 12% of cases with a complication rate of 53%. 21 The role of volume expansion as a single component of triple-H therapy for the treatment of cerebral vasospasm is supported by small studies demonstrating inconclusive results. Hypervolemia for the treatment of symptomatic vasospasm can be considered an initial treatment strategy in hypovolemic or euvolemic patients, but it is unlikely to benefi t patients who are already volume replete (ie, CVP is already >8-10 mm Hg, PAOP >14-16 mm Hg). 26 
Role of hypertonic saline in volume management.
Although hypertonic saline is not considered a traditional component of triple-H therapy, it is commonly utilized for the reduction of intracranial pressure (ICP) and may have clinical benefi ts in certain SAH populations. Patients with poor clinical grade SAH who remain unresponsive after initial resuscitation generally have globally reduced cerebral blood fl ow and areas of severe vasospasm resulting in loss of autoregulation, raised ICP, and cerebral ischemia. A prospective study evaluated the effects of hypertonic saline in 44 patients with poor grade SAH. Patients were given a 2 mL/kg infusion of hypertonic saline 23.5% over 10 to 30 minutes. Administration of hypertonic saline increased arterial blood pressure, reduced intracranial pressure, and improved cerebral blood fl ow, brain tissue oxygenation, and brain tissue pH. The duration of effect for most parameters was between 2 and 4 hours. 27 Although the data are limited, hypertonic saline may provide a reasonable fl uid alternative for patients with poor grade SAH and increased ICP.
Albumin versus crystalloids for volume expansion.
The addition of albumin to 0.9% sodium chloride fl uid management is a frequently employed strategy. Albumin is believed to be neuroprotective via several potential mechanisms of action, including increasing serum oncotic pressure, increasing antioxidant and scavenger effects, improving microcirculatory blood fl ow, and reducing infl ammatory response. 28 Studies of triple-H therapy frequently use albumin in their management; however, few studies have evaluated albumin compared to crystalloid monotherapy. An observational study of 140 patients demonstrated a trend toward reduced vasospasm (28% vs 19%; P = .2) and improved clinical outcomes at 3 months in patients who received albumin to maintain a CVP greater than 8 mm Hg. The same research group evaluated the safety and effi cacy of escalating doses of albumin 25% in a recent pilot study of 47 adult subjects with SAH. All patients received 0.9% sodium chloride at 80 to 125 mL/h and maintained a goal CVP of 5 to 8 mm Hg. The albumin dosing strategies evaluated were albumin 0.625 g/kg, 1.25 g/kg, 1.875 g/kg, and 2.5 g/kg per day for up to 7 days. Doses up to 1.25 g/kg were generally well tolerated, but the study was stopped prematurely due to fl uid overload resulting in pulmonary edema in 2 of the fi rst 7 patients in the albumin 1.875 g/kg group. 29 Albumin is generally considered safe, but certain critically ill subpopulations (eg, trauma) have demonstrated worsening mortality when administered albumin. 30 A phase III study to evaluate the effi cacy of albumin is currently underway and is needed prior to making any defi nitive conclusions about the use of albumin in SAH patients.
Blood products for volume management and oxygen delivery. Although in complete contrast to the hemodilution component of triple-H therapy, administration of blood products (mainly packed red blood cells [PRBC]) has been a strategy to increase intravascular volume and improve oxygen delivery to areas of brain ischemia. A prospective study of 35 consecutive patients with SAH or traumatic brain injury without cardiac disease measured local brain tissue oxygen partial pressure (PbtO 2 ) pre and post PRBC transfusion. A mean PbtO 2 increase of 15% occurred in 74% of patients with an average posttransfusion rise in hemoglobin of 1.4 ± 1.1 g/dL. In a prospective registry study of 611 patients, a higher hemoglobin nadir (9.9 ± 2.1 vs 8.6 ± 1.8; P < .001) and average daily hemoglobin value (11.7 ± 1.5 vs 10.9 ± 1.2; P < .001) was associated with greater functional independence at discharge (modifi ed Rankin Scale, 0-3) and reduced risk of poor outcomes. 31 A prospective study of 44 patients with SAH and high risk for vasospasm randomized patients to a goal hemoglobin concentration of 10 g/dL or 11.5 g/dL. Patients with the goal Hgb of 11.5 g/dL received more PRBC (3 vs 2 units; P = .045). The number of cerebral infarctions on MRI (30% vs 41%), NIH Stroke Scale scores at 14 days (1 vs 2), and independence rate at 14 days (65% vs 44%) were numerically improved with the higher hemoglobin concentration; however, these results were not statistically signifi cant. 32 Based upon the current evidence, recommendations have been made to maintain a hemoglobin concentration of at least 8 to 10 g/dL, with some neurointensivists advocating for ≥10 g/dL in SAH patients with active cerebral ischemia. 14, 33 However, transfusion of PRBC is not without risks, 34 and a recent retrospective cohort study found that PRBC transfusion was independently associated with increased mortality in SAH patients (odds ratio [OR], 3.16; 95% CI, 1.02-9.69). 35
Hemodilution
Hemodilution reduces blood viscosity, reverses hypovolemia, increases cardiac output, and distends the vasospastic artery, ultimately improving blood fl ow through the vasospastic arterial vasculature. Hemodilution and reduced blood viscosity can be accomplished by either isovolemic or hypervolemic strategies. A prospective study of 8 patients evaluated the effects of isovolemic or hypervolemic hemodilution on cerebral blood fl ow. Isovolemic hemodilution on day 1 was accomplished by whole blood removal with simultaneous equal volume replacement with dextran 70% and albumin 4% to obtain a hematocrit value of 28%. On day 3, patients were transitioned to hypervolemic hemodilution through the autotransfusion of the blood withdrawn on day 1 plus equal parts of dextran and albumin (mean additional volume of 1.1 L). Regional cerebral blood fl ow was measured 60 minutes after each intervention. Isovolemic hemodilution caused modest increases in global cerebral blood fl ow; after hypervolemic hemodilution, cerebral blood fl ow returned to baseline. Additionally, the oxygen delivery capacity was reduced and hemodilution was not effective at reducing the area of brain ischemia. 36 Hemodilution appears to be effective at reducing blood viscosity and may improve cerebral blood fl ow; however, these effects may be countered by the reduced oxygen-carrying capacity of the hemodiluted blood. Therefore, intentional hemodilution cannot be routinely recommended for prophylaxis or treatment of cerebral vasospasm.
Hypertension
Patients with SAH often develop increased ICP due to the hemorrhage volume, increased cerebrospinal fl uid outfl ow resistance, hydrocephalus, vasoparalysis, distal cerebral arteriolar vasodilation, and/or reactive hyperemia after hemorrhage. Consequential loss of cerebral autoregulation results in supraphysiologic cerebral perfusion pressure demands to maintain adequate perfusion of the brain. Administration of vasoactive agents can produce a sustained increase in arterial blood pressure, which results in improved cerebral perfusion pressure, cerebral blood fl ow, and brain tissue oxygenation.
Vasoactive agents are utilized to prevent and treat cerebral ischemia, a potential consequence of cerebral vasospasm, rather than to directly treat and reverse cerebral vasospasm. Prophylactic vasoactive medication therapy is generally used as necessary to maintain blood pressures required to prevent cerebral infarction, while attempting to minimize the risk of rebleeding. Treatment with vasoactive medications typically targets a higher systolic blood pressure or MAP goal, with dosages titrated to increase cerebral blood fl ow and reduce neurological defi cits associated with vasospasm. For example, in a study of 58 patients with confi rmed cerebral vasospasm after SAH, vasopressors (primarily dopamine) were used to induce arterial hypertension with a systolic blood pressure of up to 240 mm Hg in patients with secured aneurysms and up to 160 mm Hg in patients with unsecured aneurysms. Neurologic deterioration was reversed in 81% of patients, with sustained benefi t in 74% of patients. 37 In a study of normovolemic patients, induction of hypertension to 25% to 50% above normal systolic arterial blood pressure resulted in neurological defi cit improvement in 17 of 24 cases, indicating that hypertension may provide benefi ts without induced hypervolemia. 38 A variety of vasopressor options exist for the induction of hypertension; dopamine, phenylephrine, and norepinephrine are most commonly utilized in clinical practice. In a study of 13 SAH patients suspected of having clinical vasospasm and ischemia, dopamine administration (doses up to 20 mcg/kg/min) raised MAP from 90 ± 11 mm Hg to 111 ± 13 mm Hg. This increased cerebral blood fl ow in 54% of patients, placing them out of the ischemic range. Interestingly, reduced cerebral blood fl ow was identifi ed in nonischemic territories, which creates uncertainty about the ability to predict a universal response of cerebral blood fl ow to increased arterial pressures. 39 Norepinephrine targeted to achieve an increase in systolic Volume 49, November 2014 blood pressure of 20 to 60 mm Hg above symptomatic baseline, resulting in a systolic blood pressure of 140 to 190 mm Hg, was effective at reversing ischemic symptoms in a series of 7 patients with cerebral vasospasm. 40 In a safety study of 24 patients, 67% with cardiac disease, phenylephrine was utilized to increase MAP by 25%, with a further increase by 35% if no clinical improvement was observed. Neurological improvement occurred in 88% of patients. Phenylephrine did not result in reduced cardiac index measurements, and there were no occurrences of pulmonary edema or myocardial infarction. 41 Arginine vasopressin (0.01-0.04 units/min) in addition to maximal phenylephrine therapy (4-5 mcg/kg/min) was evaluated in a group of 22 patients who were at very high risk for vasospasm or who were already exhibiting clinically symptomatic vasospasm. MAP was maintained at >100 mm Hg for prophylaxis and >110 mm Hg for symptomatic patients. Vasopressin was effective at allowing the reduction of phenylephrine dosage without reducing serum sodium concentrations or causing detrimental effects on vasospasm, ICP, or cerebral perfusion pressure. 42 Myocardial injury is not uncommon after SAH and is likely mediated by the release of catecholamines due to hypoperfusion. Inotropic agents improve cardiac output and therefore should increase cerebral blood fl ow; however, data regarding their effectiveness for cerebral vasospasm are mixed. The use of dobutamine to prophylactically elevate cardiac index by 25% compared to norepinephrine-induced hypertension (MAP > 100 mm Hg) failed to decrease the incidence of angiographic vasospasm in the fi rst 14 days of treatment. 43 In a study of 23 patients with SAH who failed to respond to preload enhancement with fl uids, the addition of dobutamine 5 to 10 mcg/ kg/min was effective at reversing ischemic symptoms in 78% of patients. 44 A more recent study of 16 patients with cerebral vasospasm demonstrated that dobutamine enhancement of cardiac output alone, without changes in MAP, was effective at increasing cerebral blood fl ow. 25 Milrinone has both inotropic and vasodilatory effects and may provide an alternative with additional mechanistic benefi ts over dobutamine. Milrinone is a selective inhibitor of cyclic adenosine monophosphate-specifi c phosphodiesterase III, an important component of the cerebrovascular smooth muscle. It may also have anti-infl ammatory affects mediated via inhibition of interleukins 1B and 6. 45 The addition of milrinone (0.1-0.2 mg/kg intravenous bolus, then 0.75-1.25 mcg/kg/min) to a standard of care protocol for the treatment of patients with symptomatic vasospasm was found to be safe, 46 but comparative prospective studies are needed before conclusions can be made regarding its effi cacy.
Comparative studies evaluating vasopressor options for the prevention and management of patients with cerebral vasospasm following SAH are unavailable. Therefore, dopamine, norepinephrine, or phenylephrine are all considered to be acceptable options and should be selected based on pharmacologic differences and desired patient-specifi c response. Arginine vasopressin, at a dose of 0.01 to 0.04 units/ min, can be added as an additional vasopressor when primary vasopressor therapy has been maximized without achieving desired effects. Treatment of cerebral vasospasm via augmentation of cardiac index may be useful in patients with reduced cardiac output and hypervolemia; however, prophylactic utilization of inotropic agents to overdrive cardiac index as a mechanism of preventing cerebral vasospasm cannot be recommended at this time.
Summary of Triple-H Therapy Recommendations
Hypovolemia can occur in patients with SAH and should be avoided due to its association with worse clinical outcomes. In general, intravascular volume management should prophylactically target euvolemia with utilization of an isotonic crystalloid as the preferred fl uid for volume replacement. 15 Hypervolemia with hypertension may have a role in treating cerebral vasospasm; however, the specifi c benefi t of the hypervolemia component requires further evaluation. Addition of albumin and/or PRBC may be useful in certain patients, but more evidence is needed before defi nitive recommendations can be made. Intentional hemodilution to achieve a lower hemoglobin or hematocrit value and improve blood rheology should be avoided in most cases. Volume status should be routinely monitored and the use of CVP monitoring or a transpulmonary thermodilution system 47 in patients with central venous access may provide additional tools to assess a patient's volume status. A target CVP of ≥ 8 mm Hg has been utilized in many clinical studies; however, given the inability of CVP to reliably estimate intravascular volume, response to a CVP measurement should be interpreted on an individualized patient basis. 14 Induced hypertension increases cerebral blood fl ow and cerebral perfusion pressure and is an effective method to treat delayed cerebral ischemia. Blood pressure targets can utilize predefi ned systolic or MAP goals or a percentage increase from baseline blood pressure with further adjustments made based upon individual patient neurological response. In general, there is a revised recommendation for the use of euvolemicinduced hypertension rather than triple-H therapy as the initial method for treatment of most patients with cerebral vasospasm. 15, 22, 48 
Calcium Channel Blockers
Calcium channel antagonists prevent calcium ion entry into smooth muscle cells during depolarization, causing inhibition of vasoconstriction. Cerebrovascular smooth muscle is more sensitive to changes in extracellular calcium concentrations than the systemic arterial smooth muscle. Moderate cerebral vasodilation has been demonstrated with the administration of calcium channel antagonists, and therefore it is considered the main mechanism for modulating the incidence and severity of cerebral vasospasm and delayed cerebral ischemia. 49, 50 Additionally, nimodipine may have other benefi cial effects on patient outcomes that are independent of its ability to prevent cerebral vasospasm. 51 Unfortunately, not all of the calcium channel antagonist effects are benefi cial. Administration is associated with decreases in MAP and cerebral perfusion pressure (CPP), and recent data suggest that prevention of these decreases in MAP and CPP via the use of vasopressor therapy may be necessary to prevent decreased PbtO 2 and cerebral blood fl ow. 52 Nimodipine and nicardipine are the most wellstudied calcium channel antagonists for the prevention of cerebral vasospasm and delayed cerebral ischemia. Sixteen studies, which included a total of 3,361 patients, were recently reviewed by the Cochrane Stroke Group (Figures 1 and 2) . 53, 54 The combined results of the studies demonstrate that calcium channel antagonists reduce the risk of poor outcome (death or dependence), with those benefi cial results being driven mostly by nimodipine. 51, [55] [56] [57] [58] [59] [60] [61] [62] [63] The largest randomized multicenter doubleblind placebo controlled study of nimodipine evaluated 554 patients with SAH. Within 96 hours of ictus, patients received nimodipine 60 mg orally every 4 hours for 21 days or placebo. The primary endpoint was incidence of cerebral infarction, ischemic neurological defi cits, and outcome 3 months after study entry. Compared to placebo, nimodipine reduced cerebral infarction (22% vs 33%; P = .003) and poor outcomes (20% vs 33%; P < .001) and demonstrated a trend toward reduced rebleed rates (9% vs 14%; P = .077). The primary differences in outcome were a reduction in death and disability in nimodipine-treated patients. Nimodipine was not without adverse effects. Nimodipine reduced both systolic (mean reduction of 7.1 mm Hg) and diastolic blood pressure (mean reduction of 3.6 mm Hg), but this did not result in increased heart rate, increased fl uid administration, or decreased urine output. Additional adverse effects requiring discontinuation of nimodipine were rash (2 patients), cardiovascular effects (3 patients with headache, 1 with fl ushing, 1 with hypertension, and 1 with hypotension), and liver function abnormalities (4 patients). 55 Nicardipine may provide an intravenous alternative to nimodipine. The largest study of intravenous nicardipine to date was a multicenter prospective randomized placebo-controlled trial evaluating 906 patients with SAH. Patients were randomized from hospital days 0 to 7 to receive either high-dose intravenous nicardipine (0.15 mg/kg/h) or placebo for up to 14 days following SAH. The primary endpoint of the study was neurological recovery at 3 months following SAH, and it was not signifi cantly different between nicardipine (55% with good recovery; mortality 17%) and placebo (56% with good recovery; mortality 18%). The incidence of symptomatic vasospasm was higher in placebo-treated patients compared to the nicardipine group (46% vs 32%; P < .001), and more patients in the placebo group required intentional hypervolemia, induced hypertension, and/or hemodilution administered to treat symptomatic vasospasm (38% vs 25%; P < .001). The most common adverse effect of nicardipine was hypotension, which occurred in 35% of patients; life-threatening hypotension occurred in only 3% of patients. Additional adverse effects were phlebitis (22.3%) and pulmonary edema in combination with azotemia (6%). 64 Due to these increased rates of adverse effects, a follow-up study randomized patients to 2 different doses of nicardipine to evaluate whether lower doses could be effective with improved safety outcomes. This multicenter prospective study randomized 365 SAH patients to high-dose (0.15 mg/kg/h) or lower dose (0.075 mg/kg/h) intravenous nicardipine for up to 14 days following SAH. Symptomatic vasospasm occurred in 31% of each group, and there were no differences in the percentage of good neurological outcomes (58% vs 59%) or mortality (11% vs 12%) at 3 months between the high-dose and lower dose treatment groups, respectively. Although there were no differences in clinical outcomes, lower dose nicardipine was better tolerated. Severe hypotension with evidence of end organ ischemia occurred in 1.1% of the high-dose group compared to 0.6% of the lower dose group. Pulmonary edema also occurred more frequently in the high-dose group compared to the low-dose group (34% vs 20%; P < .01). 65 Compared to other available pharmacotherapy interventions, nimodipine has currently demonstrated the best evidence for improved clinical outcomes in patients with SAH. Prophylactic oral nimodipine therapy administered at 60 mg every 4 hours for 21 days after SAH hemorrhage is recommended for all SAH patients. 14, 15 If hypotension occurs, nimodipine can be administered as 30 mg every 2 hours. 14 If decreases in MAP and CPP are not alleviated by adjusting the nimodipine dose and interval, then the administration of vasopressor therapy may be required to safely continue nimodipine therapy.
Intravenous nicardipine may provide an alternative to nimodipine therapy in patients who cannot tolerate oral therapy or in patients in whom adequate absorption is questionable; however, the clinical outcome benefi ts with nicardipine have not been as reproducible as those demonstrated by nimodipine. Lower dose intravenous nicardipine (0.075 mg/kg/h) is equivalent to high-dose nicardipine and is better tolerated.
Magnesium
Hypomagnesemia occurs in more than 50% of patients with SAH and has been associated with poor outcomes. 66 Magnesium, a divalent cation, functions as a noncompetitive calcium antagonist via binding to voltage-dependent calcium channels. This action promotes vasodilation by inhibiting calcium entry into the cell, inhibiting vascular smooth muscle contraction, and decreasing glutamate release. Therefore, it may inhibit cerebral vasospasm and confer potentially neuroprotective effects similar to the dihydropyridine calcium channel antagonists. 67, 68 Several clinical studies have evaluated the effects of magnesium on cerebral vasospasm and neurological outcomes in patients with SAH. [69] [70] [71] [72] [73] [74] [75] A recent multicenter phase III randomized placebo-controlled study enrolled 327 patients with SAH within 48 hours of hemorrhage onset. The primary outcome was a favorable neurological outcome at 6 months. Patients were randomized to receive magnesium 20 mmol (5 g) over 30 minutes followed by a continuous infusion of 80 mmol (20 g) per day for up to 14 days after hemorrhage or placebo (0.9% sodium chloride). The magnesium infusion was adjusted to achieve a magnesium concentration twice the patient's baseline value up to a maximum of 2.5 mmol/L. The percentage of patients with favorable outcome at 6 months was similar in the magnesium (64%) and placebo (63%) groups. The percentage of patients with clinical vasospasm was also similar in the magnesium (25%) and placebo (18%) groups. Magnesium infusions were discontinued in 3 patients because of severe limb weakness, refractory hypernatremia, and severe hypocalcaemia. There were no differences in the rates of hypotension, cardiac failure, acute renal failure, pneumonia, sepsis, pulmonary embolism, myocardial infarctions, or gastrointestinal bleeding between the treatment groups. 73 A recent meta-analysis of 6 studies (875 patients) receiving intravenous magnesium demonstrated a nonsignifi cant decrease in delayed cerebral ischemia (relative risk [RR], 0.87; 95% CI, 0.36-2.09; P = .75) and decreased delayed cerebral infarction rate (RR, 0.58; 95% CI, 0.35-0.97; P = .04). The pooled relative risk for a favorable outcome at 3 months was 1.14 (95% CI, 0.99-1.31; P = .07). 72 Despite animal and phase II data showing promising results with intravenous magnesium, the most recent phase III data regarding clinical effi cacy has failed to demonstrate a clear benefi t of magnesium therapy in patients with SAH. It is possible that the lack of benefi t is due to poor penetration of magnesium into the cerebrospinal fl uid. The regimen used in the phase III clinical study was only able to increase cerebrospinal fl uid magnesium concentrations from 11% to 21% of the plasma. Even though magnesium is a relatively cheap and safe medication, it cannot be routinely recommended at this time. Rather than aggressive magnesium therapy, the current recommendation is to administer magnesium as necessary to prevent hypomagnesium. 14 
HMG-CoA Reductase Inhibitors (Statins)
The potential therapeutic benefi ts of statins have been tested in a variety of disease states, including cerebral vasospasm post SAH. Statins upregulate endothelial nitric oxide synthase and the availability of endogenous nitric oxide by inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase. This corrects the imbalance between the nitric oxide and endothelin pathways, which is believed to be a main contributor to the pathophysiology of cerebral vasospasm. 76 Additionally, statins may decrease glutamate-mediated excitotoxicity, reduce production of reactive oxygen species, and modulate the infl ammatory response via alterations in the cytokine response. 77, 78 Several prospective studies have evaluated the effects of statins (simvastatin, pravastatin, or atorvastatin) on vasospasm and delayed cerebral ischemia with mixed results. [79] [80] [81] [82] [83] [84] [85] A phase II randomized placebo-controlled trial of 80 SAH patients placed patients on pravastatin 40 mg daily or placebo within 72 hours of hemorrhage and continued therapy for up to 14 days. Vasospasm and severe vasospasm were decreased by 32% (P = .006) and 42% (P = .044), respectively, in pravastatin-treated patients. Pravastatin also decreased the incidence of vasospasmdelayed cerebral ischemia by 83% (P < .001) and mortality by 75% (P = .037). The duration of severe vasospasm was shortened by 0.8 days in the pravastatin group. Unfortunately, these impressive results have not been reproduced in more recent studies.
A phase II randomized, double-blind, placebocontrolled study of 39 statin-naïve SAH patients evaluated simvastatin 80 mg daily or placebo administered within 96 hours of hemorrhage. Therapy was continued until discharge from the intensive care unit or a maximum of 21 days. Angiographically confi rmed vasospasm occurred in 26% of simvastatin and 40% of placebo patients. Vasospasm-related ischemic infarcts occurring in 11% of simvastatin and 25% of placebo patients, but these differences were nonsignifi cant. Simvastatin therapy required discontinuation in 1 patient due to increased alanine aminotransferase and aspartate aminotransferase levels. Enthusiasm for statin therapy was further stymied when a similar study of simvastatin utilizing comparable methodology and size was unable to demonstrate any difference in outcomes. 83 A more recent study of atorvastatin evaluated whether statin therapy reduced vasospasm-induced ischemia by utilizing daily measurements of serum S100B, a biomarker for cerebral ischemia. Computed tomography was used to measure the ischemic lesion volume. Atorvastatin 40 mg once daily was administered to 142 patients for 21 days. These patients were compared to a historical control of 136 patients who were not managed with statin therapy. Atorvastatin treatment reduced the incidence of cerebral vasospasm, severity of vasospasm, volume of ischemia, and serum S100B levels, but there were no differences in rescue therapy requirements or clinical outcomes at 1 year. 84 The addition of statin therapy in statin-naïve patients with SAH appears safe and has demonstrated clinical benefi ts in most of the clinical studies to date. Completion of the ongoing Simvastatin in Aneurysmal Subarachnoid Haemorrhage (STASH) study (http:// www.stashtrial.com/home.html) should provide more defi nitive evidence to guide recommendations for routine use of statins in SAH. In the interim, if a decision is made to initiate statin therapy, statins therapy should be started within 96 hours (preferably 48 hours) post ictus and continued for 14 to 21 days. Given the aggressiveness of statin dosing utilized in most studies, liver function and creatinine phosphokinase should be monitored periodically throughout treatment to avoid the potential of rare, but clinically signifi cant, hepatotoxicity or rhabdomyolysis. Due to worsened outcomes seen after discontinuation of statin therapy in patients with ischemic stroke or myocardial infarction, statin therapy should be continued in SAH patients who were receiving these medications prior to admission. 14
Endothelin Receptor Antagonists
Endothelin receptor antagonists inhibit the binding of the potent vasoconstrictor, endothelin-1, to its receptors on vascular smooth muscle cells. Clazosentan, as selective endothelin-1 receptor antagonist, has been the most well studied to date. [86] [87] [88] [89] [90] An early phase II study of clazosentan (CONSCIOUS-1) demonstrated that clazosentan produced dose-dependent reductions in angiographic vasospasm, with a 65% relative risk reduction at the highest dose of 15 mg/h. 86 Based upon these results, 2 phase III studies were conducted to evaluate clazosentan 5 mg/h or 15 mg/h compared to placebo (CONSCIOUS-2 and CONSCIOUS-3). 87, 90 The primary outcome evaluated was a composite of all-cause mortality, vasospasmrelated new cerebral infarcts, delayed ischemic neurological defi cit due to vasospasm, and rescue therapy for vasospasm. In the CONSCIOUS-2 study, 768 patients were randomized to clazosentan 5 mg/h and 389 patients received placebo for up to 14 days. The composite endpoint occurred less frequently in the clazosentan group (21%) compared to the placebo group (25%), however this difference was not signifi cant (P = .1). The difference between groups was driven by a reduced need for rescue therapy for cerebral vasospasm with clazosentan. Interestingly, poor functional outcomes (Glasgow Outcome Scale ≤ 4) occurred more frequently in the clazosentan-treated patients (29% vs 25%, respectively; P = .1) and mortality between groups was the same. Clazosentan adverse events requiring discontinuation of the study drug were pulmonary edema, hypotension, cerebrovascular spasm, pleural effusion, and cerebral infarction. Of the adverse events reported, lung complications, anemia, and hypotension were more common with clazosentan than placebo. 87 Based upon the results of this study, CONSCIOUS-3 was stopped early after enrolling only 577 of its planned 1,500 patients. The results of CONSCIOUS-3 demonstrated similar fi ndings to CONSCIOUS-2 for the 5 mg/h clazosentan dose. The clazosentan 15 mg/h dose was effective for reducing vasospasm-related morbidity, but it did not improve functional outcomes (Glasgow Outcome Scale ≤ 4 occurred in 24% of placebo vs 28% of clazosentan 15 mg/h, respectively; P = .266).
Results from studies of clazosentan to date demonstrate that it is effective at reducing cerebral vasospasm in patients with SAH. Unfortunately, this benefi t does not translate into improved patient outcomes. Additionally, adverse events including anemia, pulmonary complications, and hypotension are more common in clazosentan patients. Therefore, the use of endothelin receptor antagonists for patients with SAH cannot be recommended at this time.
Tirilazad
Tirilazad is a non-glucocorticoid 21-aminosteroid that functions as a free radical scavenger by inhibiting lipid peroxidation. This antioxidant effect is believed to confer neuroprotective benefi ts. Interest in tirilazad for cerebral vasospasm was founded after a secondary reduction in angiographic vasospasm, via an unknown mechanism, was observed during a phase II clinical study. 91 After this initial study, 4 randomized controlled studies were conducted to evaluate the effi cacy and safety of tirilazad in patients with SAH. [92] [93] [94] [95] These studies demonstrate discordant results regarding tirilazad's effects on neurological outcomes, incidence of cerebral vasospasm, and benefi ts in men versus women. A recent meta-analysis of these studies, including a total of 3,797 patients, concluded that tirilazad does not decrease unfavorable clinical outcomes (per the Glasgow Outcome Scale) (OR, 1.04; 95% CI, 0.89-1.2) or reduce cerebral infarction rates (OR, 1.04; 95% CI, 0.89-1.22). However, a reduction in symptomatic vasospasm was observed in patients receiving tirilazad (OR, 0.8; 95% CI, 0.69-0.93). The most common adverse event of tirilazad reported was phlebitis.
A dissociation between tiralazad's effects on cerebral vasospasm and neurological outcomes currently exists. Even though tiralazad appears to be a relatively safe medication, the lack of signifi cant benefi t on clinical outcomes makes the use of this agent costly and economically unsound. 96 Therefore, its use cannot be recommended.
Cilostazol
Cilostazol, a selective inhibitor of phosphodiesterase 3, may attenuate cerebral vasospasm by increasing intracellular concentrations of cAMP, resulting in vasodilatory effects and inhibition of platelet aggregation. A recent prospective study randomly assigned patients treated by clipping within 72 hours from the onset of SAH to cilostazol 100 mg twice daily (n = 54) or usual therapy (n = 55). Symptomatic vasospasm was reduced to 13% in the cilostazol group compared to 40% in the usual care group (P = .002). Angiographic vasospasm was lower in the cilostazol group than in the usual care group (50% vs 77%; P = .006). The number of new cerebral infarctions was also lower in the cilostazol group (11% vs 29%; P = .03). However, no differences were demonstrated in clinical outcomes at 1, 3, or 6 months or the length of hospitalization between the groups. 97 Despite preliminary results demonstrating potential effi cacy for cerebral vasospasm and overall benign safety profi le, additional studies are needed before routine use of cilostazol can be recommended.
Eicosapentaenoic Acid
Rho-kinase activation and sphingosylphosphorylcholine (SPC) concentrations are elevated in patients with SAH and may play a role in the pathogenesis of cerebral vasospasm. Eicosapentaenoic acid (EPA) is an omega-3 polyunsaturated fatty acid that has been evaluated for a variety of indications due to its potential pleiotropic effects. EPA inhibits SPC-Rho-kinase-activated Ca(2+)-sensitization of the vascular smooth muscle. This inhibits vascular smooth muscle contraction and is the proposed mechanism for reducing vasospasm in patients with SAH. 98 A recent open-label prospective study evaluated EPA to no EPA in 162 patients with SAH. EPA patients received 900 mg of EPA ethyl ester 3 times daily starting after surgical clipping and continued Volume 49, November 2014 therapy for 30 days. The occurrence of symptomatic vasospasm (15% vs 30 %; P = .02) and cerebral infarction caused by cerebral vasospasm (7% vs 21%; P = .01) were lower in patients receiving EPA. The percentage of patients with a favorable outcome did not differ between the 2 groups at day 30 or day 180. Diarrhea, epigastric discomfort, and nausea were the only EPA-related adverse effects reported. 99 Although these data appear promising, prospective randomized studies are needed before any conclusions can be made regarding the utility of EPA for prevention of cerebral vasospasm in SAH patients.
Locally Administered Pharmacotherapy
Intra-arterial, intrathecal, or intraventricular administration of medications provides a targeted approach to the treatment of cerebral vasospasm. Direct administration to the site of action should result in high tissue concentrations and increased efficacy, particularly for small vessel vasospasm. However, most evidence of locally administered pharmacotherapy is based upon case series, and little is known about the pharmacokinetics and pharmacodynamics of the administered medications. 100 Therefore, it is diffi cult to determine the most appropriate medication dose or frequency of administration, and clinical application is generally accomplished by mimicking successful case reports published within the available literature.
Papaverine
Papaverine preferentially vasodilates the vascular smooth muscle of cerebral and coronary arteries by inhibiting cyclic adenosine monophosphate and cyclic guanosine 3,5 monophosphate phosphodiesterase activity. Intra-arterial administration of papaverine (doses ranging from 150-600 mg) has demonstrated good success in the treatment of cerebral vasospasm in most reported clinical experiences. [101] [102] [103] [104] [105] [106] [107] [108] [109] [110] [111] The administration technique has varied, but most studies either utilized a bolus over 60 seconds or a slow infusion of 0.1% to 0.6% solution at 1 to 7 mL/min. Papaverine administration is not without adverse events. The most noteworthy events reported include hemiplegia and seizures, but increased ICP, agitation, altered mental status, and hypotension have also been observed. 112 High exposure to papaverine may cause neurotoxicity due to altered mitochondrial cellular respiration. 113 Given the potential for adverse events and the availability of alternative intra-arterial options, papaverine cannot be routinely recommended for the treatment of vasospasm.
Calcium Channel Blockers
Nicardipine. Nicardipine manufactured for intravenous injection can be administered by intra-arterial, [114] [115] [116] intrathecal, 117 or intraventricular 118 routes for the treatment of cerebral vasospasm. Intra-arterial nicardipine was evaluated in a prospective study of 18 patients and a total of 44 vessels. Intravenous nicardipine was diluted with 0.9% sodium chloride to a concentration of 0.1 mg/mL and administered in 1 mL aliquots through a microcatheter to a maximum dose of 5 mg per vessel. Nicardipine was effective at inducing vasodilation of all vessels evaluated, and mean peak systolic velocities on TCD were reduced from pretreatment values for 4 days after infusion. Neurologic improvement was seen in 42% of patients. Increases in ICP were observed in 5 patients. 114 In a prospective case series of 6 patients, nicardipine 4 mg every 12 hours was administered intrathecally. Ventricular drains were clamped for 30 minutes following administration. Evaluation of middle cerebral artery velocity via TCD demonstrated that nicardipine had positive effects on cerebral arterial fl ow. 117 In a retrospective case series of 8 patients, intraventricular nicardipine 4 mg was administered every 12 hours for a total of 5 to 17 days. The drug was well tolerated, and 7 of the 8 patients had moderate to good functional outcomes. 118 A potential novel option for administering nicardipine is the insertion of nicardipine-releasing implants at the time of surgical intervention. A phase II prospective, randomized, double-blind evaluation of nicardipine prolonged release implants in 32 patients demonstrated that nicardipine was more effective than placebo at reducing the incidence of vasospasm (7% vs 73%; P < .05) and delayed cerebral ischemia (14% vs 47%; P < .05). 119 Although relatively little data are available on the use of locally administered nicardipine therapy, it appears to provide effective and sustained effects on the cerebral vasculature. Additionally, nicardipine appears to be associated with fewer adverse events when compared to other locally administered vasodilatory therapies.
Verapamil. Verapamil is a benzylalkylamine calcium channel antagonist that reduces the infl ux of calcium through L-type calcium channels in smooth muscle cells. Due to its effectiveness in treating coronary vasospasm, intra-arterial verapamil has been utilized in the management of cerebral vasospasm. [120] [121] [122] Data evaluating the use of intra-arterial verapamil are mostly limited to retrospective evaluations of clinical practice. In a retrospective evaluation of 12 patients with refractory vasospasm, high-dose verapamil was administered into 36 vessels at a dosage of between 25 and 360 mg (total dose per treatment of 70-720 mg) per vessel. Verapamil infusions were administered over 1 to 20.5 hours. Verapamil was effective at reversing vasospasm in 32 vessels, and 9 of the 12 patients treated had no new evidence of ischemia on computed tomography. 120 Verapamil appears to be effective at reversing cerebral vasospasm. ICP, heart rate, and blood pressure should be monitored during administration to limit adverse effects. 123
Nitroprusside
Sodium nitroprusside causes vasodilation of the vascular smooth muscle via release of nitric oxide. Intraventricular administration of nitroprusside was evaluated in a prospective study of 25 SAH patients with severe vasospasm refractory to conventional therapy. Nitroprusside 4 mg/mL was administered intraventricularly via an Ommaya reservoir in escalating dosages and frequency depending on the patient's tolerance and fall in mean fl ow velocity on TCD. The mean nitroprusside dose administered was 18.4 mg (range, 8-30 mg). An improvement in mean fl ow velocity was seen in all patients. Adverse effects related to nitroprusside in these patients were hypotension and vomiting. 124
Milrinone
Milrinone is a bipyridine inotropic vasodilator that selectively inhibits peak III cyclic adenosine monophosphate phosphodiesterase isozyme found in cardiac and vascular muscle. This activity causes increases of intracellular ionized calcium, contractile force in heart muscles, and vasodilation. Intra-arterial milrinone has been evaluated for the treatment of cerebral vasospasm. [125] [126] [127] A prospective study of 22 patients evaluated the effectiveness of intra-arterial milrinone (8 mg over 30 minutes, repeated up to a maximum of 24 mg as needed) combined with intravenous milrinone 0.5 to 1.5 mcg/kg/min for treating angiographically proven cerebral vasospasm. Intraarterial milrinone resulted in a mean increase in arterial diameter of 53% and was effective at reversing cerebral vasospasm. The most common adverse effect related to milrinone was increased heart rate, and 5 patients had vasospasm recurrence within 48 hours post intra-arterial administration.
Cisternal irrigation of milrinone has also been evaluated. In a study of 12 patients, lactated Ringer solution containing urokinase (120 IU/mL), ascorbic acid (3.5 mg/mL), and milrinone (3.6 mcg/mL) was continuously infused at 30 mL/h for up to 2 weeks. In this study, only 3 of the 12 patients developed symptomatic cerebral vasospasm, with 1 patient suffering a permanent neurological defi cit. 128
Thrombolytics
Locally administered intrathecal thrombolytics enhance the conversion of plasminogen to plasmin by binding to fi brin, initiating fi brinolysis. This action can speed the clearance rate of blood from the basal cisterns and ventricles and may reduce the incidence of cerebral vasospasm and complications associated with SAH.
Urokinase and alteplase are the most well-studied thrombolytics in patients with SAH, but the dosages and administration frequencies that were evaluated vary substantially. [129] [130] [131] [132] [133] [134] [135] [136] Urokinase dosages of 6,000 to 120,000 IU daily and durations of 1 to 12 days have been utilized. Similarly, alteplase dosages from 1 to 10 mg have been utilized with variable durations. More recently, administration of alteplase at dosages of 1 to 3 mg (followed by clamping the external ventricular drain for 1 hour) twice daily until nearly complete clearance of blood from the third/fourth ventricles has been suggested. 134 A meta-analysis of 5 randomized controlled trials (total of 465 patients) concluded that administration of intrathecal thrombolytics reduced poor outcomes (OR, 0.52; 95% CI, 0.34-0.78; P < .01) and delayed neurologic defi cits (OR, 0.54; 95% CI, 0.34-0.87; P = .01), angiographic vasospasm (OR, 0.32; 95% CI, 0.15-0.70; P < .01), and chronic hydrocephalus (OR, 0.33; 95% CI, 0.15-0.74; P < .01) without increasing hemorrhagic and infectious complications. 133 Intrathecal thrombolytics are not without risk, and exacerbations of perihematomal edema and sterile meninigitis have occurred. 134 Despite the potential for improved outcomes with intrathecal thrombolytic administration, routine administration is not currently recommended. 14, 77, 137 
CONCLUSION
Cerebral vasospasm signifi cantly increases morbidity and mortality after SAH. Clinical studies have tested a variety of pharmacotherapy interventions for the prevention and treatment of cerebral vasospasm. Unfortunately, the majority of these studies are not large randomized trials, making it diffi cult to construct clear recommendations regarding the effi cacy and safety of most pharmacologic interventions. Volume 49, November 2014
Euvolemia is recommended over hypervolemia as a preventative method for cerebral vasospasm. Prophylactic hemodilution or administration of blood products to maintain a specifi c target hemoglobin/hematocrit concentration cannot be routinely recommended. Initiation of triple-H therapy may provide a reasonable approach to the treatment of cerebral vasospasm and delayed cerebral ischemia. However, considerable debate still exists regarding which of the 3 components (hypervolemia, hemodilution, or hypertension) should be routinely employed. Therefore, practice patterns at individual institutions still vary substantially. Hypertension remains the most steadfast component of triple-H therapy for improving cerebral perfusion and oxygenation, thus current guidelines recommend a euvolemic-induced hypertension model. 15 Triple-H therapy is not without risks, and patients should be closely monitored for signs of cardiac failure, pulmonary and cerebral edema, electrolyte abnormalities, and rupture of unsecured aneurysms. Recent evidence suggests that euvolemic fl uid management with induction of hypertension may provide the preferred initial approach to treatment of patients with cerebral vasospasm and delayed cerebral ischemia.
Nimodipine is the one pharmacologic intervention that has most consistently demonstrated beneficial effects on patient outcomes in prospective studies and should be routinely employed for patients with SAH. Intravenous nicardipine has demonstrated the ability to reduce the incidence of cerebral vasospasm and offers an alternative to oral nimodipine; however, it has yet to demonstrate clear improvements in clinical outcomes. Inducing hypermagnesemia with the administration of high doses of intravenous magnesium demonstrated benefi ts in smaller pilot studies; however, given the equivocal results of a recent large randomized trial, routine use of this agent cannot be recommended. Standard of care magnesium supplementation should be utilized as necessary to avoid hypomagnesemia in patients with SAH. It is recommended that patients who are on statin therapy prior to admission continue statin therapy. Results of ongoing large prospective studies are required before a recommendation can be made to routinely add statin therapy in statin-naïve patients with SAH. Locally administered pharmacotherapy provides a targeted approach to the treatment of cerebral vasospasm. However, most evidence to date consists of case series, and therefore it is diffi cult to determine the most appropriate therapy and implementation strategy. Of the currently available agents evaluated for local administration, nicardipine and thrombolytics appear to be the most intriguing.
SAH is a multifaceted disease, and most patients require surgical and pharmacologic intervention to improve neurological outcomes. Given the complexity of SAH disease and the multitude of treatment options for the prevention and treatment of cerebral vasospasm and delayed cerebral ischemia, the efforts of a multidisciplinary health care team are critical. This approach allows for individualized patient therapy and increases the likelihood that pharmacologic interventions and monitoring strategies are based on the best available evidence, ultimately increasing the probability of optimal patient outcomes. 36. Ekelund A, Reinstrup P, Ryding E, et al. Effects of iso-and hypervolemic hemodilution on regional cerebral blood fl ow and oxygen delivery for patients with vasospasm after aneurysmal subarachnoid hemorrhage. Acta Neurochir (Wien). 2002;144:703-712; discussion 12-13. 37. Kassell NF, Peerless SJ, Durward QJ, Beck DW, Drake CG, Adams HP. Treatment of ischemic defi cits from vasospasm
